Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology | JAMA Network

Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial | Targeted and Immune Cancer Therapy | JAMA Oncology | JAMA Network

May 2018

Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous PolyposisSecondary Analysis of a Randomized Clinical Trial

N. Jewel Samadder, MD, MSc^1,2,3; Scott K. Kuwada, MD⁴; Kenneth M. Boucher, PhD^1,5; et alKathryn Byrne, MD²; Priyanka Kanth, MD²; Wade Samowitz, MD^1,6; David Jones, PhD^1,7; Sean V. Tavtigian, PhD^1,7; Michelle Westover, BS¹; Therese Berry, BS¹; Kory Jasperson, MS¹; Lisa Pappas, MStat¹; Laurel Smith, BS¹; Danielle Sample, MPH¹; Randall W. Burt, MD^1,2,7; Deborah W. Neklason, PhD^1,7,8

Author Affiliations Article Information

JAMA Oncol. 2018;4(5):671-677. doi:10.1001/jamaoncol.2017.5431